APG vs JBHT

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full solvency assessment. Despite strong recent price performance and robust revenue and earnings growth, the stock trades at a steep valuation (P/E of 116.19 vs. sector average of 48.97) far above its Graham Number of $7.99 and intrinsic value of $10.62, suggesting significant overvaluation. Earnings quality is deteriorating, with 3 of the last 4 quarters missing estimates by an average of -32.33%, and YoY EPS has declined by 41.2% despite positive Q/Q growth. Heavy insider selling of $20.69M in the last 6 months and a bearish technical trend further reinforce caution.

JBHT presents a dichotomy between strong recent price momentum and deteriorating fundamental value markers. The Piotroski F-Score of 4/9 indicates stable but mediocre financial health, while the current price of $227.04 sits significantly above both the Graham Number ($72.1) and the Intrinsic Value ($180.84). While earnings growth is robust at 23.6%, the negative revenue growth and bearish insider activity suggest the current valuation is driven by momentum rather than organic expansion. The stock is currently trading at a premium that exceeds analyst targets and intrinsic estimates.